Ventilatory failure caused

In order to effectively treat respiratory acidosis, the causative process must be identified and treated. If a cause is identified, specific therapy should be started. This may include naloxone for opiate-induced hypoventilation or bronchodilator therapy for acute bronchospasm. Because respiratory acidosis represents ventilatory failure, an increase in... 

In critically ill patients who have ventilatory failure from various causes (eg, severe bronchospasm, pneumonia, chronic obstructive airway disease), it may be necessary to control ventilation to provide adequate gas exchange and to prevent atelectasis. In the ICU, neuromuscular blocking drugs are frequently administered to reduce chest wall resistance (ie, improve thoracic compliance) and ineffective spontaneous ventilation in intubated patients. 

The seven serotypes of botulinum toxin produced by Clostridium botulinum are the most toxic substances known. They are associated with lethal food poisoning after the consumption of canned foods. This family of toxins was evaluated by the United States as a potential biological weapon in the 1960s and is believed to be an agent that could be used against our troops. Unlike other threat toxins, botulinum neurotoxin appears to cause the same disease after inhalation, oral ingestion, or injection. Death results from skeletal muscle paralysis and resultant ventilatory failure. Because of its extreme toxicity, the toxin typically cannot be identified in body fluids, other than nasal... 

Along with airaray problems, breathing difficulties are the major cause of morbidity and death in patients with poisoning or drug overdose. Patients may have one or more of the following complications ventilatory failure, hypoxia, or bronchospasm. 

A Assessment Ventilatory failure has multiple causes, including failure of the ventilatory muscles, central depression of respiratory drive, and severe pneumonia or pulmonary edema. Examples of drugs and toxins that cause ventilatory failure and the causative mechanisms are listed in Table 1-1. 

B. Complications. Ventilatory failure is the most common cause of death in poisoned patients. 

Respiratory failure may be classified as hypoxemic (type 1) or hypercapnic (type II or ventilatory failure) (3), either of which may be acute and chronic. Hypoxemic respiratory failure is due to failure of the lungs, caused by acute (cardiogenic pulmonary edema, pneumonia, acute respiratory distress syndrome) or chronic (emphysema, interstitial limg disorders) diseases (Tables 1 and 2). It is characterized by hypoxemia with normocapnia or hypocapnia. In these conditions central respiratory drive is high and there is sufficient alveolar ventilation (VA) to eliminate CO2 and prevent hypercapnia. 

Hypercapnic respiratory failure is due to failure of the ventilatory pump caused by acute (drug overdose, acute neuromuscular diseases) or chronic (chest wall abnormalities, chronic neuromuscular diseases) disorders. It is characterized by alveolar hypoventilation, which leads to hypercapnia with coexistent, usually mild, hypoxemia. The central drive may be globally reduced with the fall in Pa02 resulting from the increase in alveolar CO2. More commonly, the drive remains high, but the mechanical load on the respiratory systan is too great or the capacity of the muscles too low to ensure efficient CO2 elimination (Fig. 1). 

The most accepted indication for NPPV is diurnal hypercapnia in a stable state because it is the signature of overt ventilatory failure. Most recommendations concern patients with NMD and, in particular, patients with Duchenne muscular dystrophy in whom ventilatory support should be considered when daytime Paco2 exceeds 6 kPa (45 mmHg) (23-27). No guidelines or recommendations are available for the other causes of hypoventilation such as OSA or CF, but it seems reasonable to also consider diurnal hypercapnia as a criterion to propose NPPV in these patients. 

---